»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ W{m_yEOf
Vx z`
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 ui
RO,B}z
po\(O8#5U
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© "%}24t%
1.Antigen presenting cell£¨APC£©
'Zs3b
4n8
2.Activation induced cell death£¨AICD£© j(A>M_f;
3.Chemokine 2##;[
4.Major histocompatibility complex£¨MHC£© OxQ 5P;O
5.immunotolerance O^J=19Ri
nW)?cQ
I
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© [QFAkEJ--o
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ 7KesfH?
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà ~R&rQJJeJ
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ i#98KzE
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ <Drm#2x!E
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã ~&?57Sw*m
5vFM0
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© <6Y|vEo!N
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ *I!R0;HT
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ #+QJ5VI:
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ mPU}]1*p
^k*%`iQ
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ :zX^H9'E<(
oi
m7=I0
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 I{Ip
WMHYOJR
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ ~j>yQ%[v
1.Antigenic determinant E
nGh&]
2.IgSF R%4Yg(-Q
3.MBL;¾¶ &@,lF{KTL
4.chemokine S{?l/*Il*_
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ 5kGQf
6.TCR-CD3¸´ºÏÎï v-N4&9)%9
7.FADD£¨Fas-associated protein with death domain£© "b402"&
8.AIDS *v%gNq
9.Tumor rejection antigen }]H7uC!t
10.AICD 0r_~LN^|[
ZBR^$?nj
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ 6/#+#T
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© 9+MW13?
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ Lc?"4
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ @sG*u >
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì w&f>VB~,1
[Rub
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ .?rs5[th*
M*bsA/Z
X3 1%T"
רҵ¿Î ÃâÒßѧ hSxK*.W*3
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê y\j[\UZKO
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell 50dN~(;p
5. Fc¦Å receptor 6. Cytokine WMnSkO
¶þ¡¢ ÎÊ´ðÌâ P=1Ku|k
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 @67GVPcxl
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ OM^`P
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ ?]bx]Y;
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 )X," NJG
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠ*z6A ~U
={v(me0ZPb
9{U@s
N
%'(8%;
0sA`})Dk
/eU\B^k
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ]@cI _n
%).I&)i
J @~g>
רҵ¿Î ÃâÒßѧ f3n^Sw&Q(Q
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê `KLr!<i()
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen [_`yy
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin <+
r~?X_
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test !5h-$;
9. Hybridoma technic 10.Mitogen BMQ4i&kF|
11.Dentritic cell 12.Immunoproliferation z>0$SBQ-
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ G5OGyQp
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ Z_dL@\#|
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ_g9j_
x:=
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ nj00g>:>
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ jTNt!2 :B
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ 6C<GYzzo
k:iy()n[
!mWm@}Ujg
4_CL1g
nL[OwfPj
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ hT_Q_1,
LkK&<z
G#f3
WpD
רҵ¿Î ÃâÒßѧ T*Ge67
Ò»¡¢ Ãû´Ê½âÊÍ o(> #}[N}
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï 3LJ\y
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà @c"s6h&
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ {,6J*v"o
¶þ¡¢ ÎÊ´ðÌâ bQ
0Ab"+D
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ Sfc,F8$&N
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ /pU`-
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ Y`$\o
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ 0wSy[z4V
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ x
QzW6H
|
W?!rqo2SP
3m4
sh~
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ c68y\
Q3$DX,8?
c05-1
רҵ¿Î ÃâÒßѧ vF~q ".imC
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê /[/{m ]
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR PBE i"`i
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA o$U{.#
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM cH:&S=>h
¶þ¡¢ ÎÊ´ðÌâ 9AQ,@xP|
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ qkp0' f*}
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ R^$EnrY(<
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ nUX3a'R
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ |)0Ta9~
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ &%)F5PT
0yMHU[):~
c(b`eUOO
?8< =.,r
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ $n
IE;idk
U,fPG/9
(Nd)$Oq[4
רҵ¿Î ÃâÒßѧ Y$)y:.2#
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê Vu4LC&q
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule eOXu^M>:F
5. Autogous mixed lymphoyte reaction 0(Z:QqpU$
¶þ¡¢ ÎÊ´ðÌâ H.]<fvP
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ MU `!sb*
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ '
IVC!uL,%
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ{9j0k`A
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ Q?([#
M_cm,|FF
Q.V@Sawe5
g1 y@z8Z{
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 4 R8Qn^
H+gB|
\)aFYDq#\
רҵ¿Î ÃâÒßѧ cf"!U+x
6e5A8e8"]
asy:[r"
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê rG[
2.\&
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance
e~,+rM
5. Delayed type hypersensitivity *] >R
¶þ¡¢ ÎÊ´ðÌâ N6S@e\*
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ Z3u6m0!
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ ":=h1AJY
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ N693eN!
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷ÓᣠUxMei
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠKMl3`+i
!g|[A7<|
7[R`52pP
vYo~36
OP_\V8=
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ hX-^h2eV
q 4Ok$~"I
jsKKg^g
רҵ¿Î ÃâÒßѧ W55kR.X6M
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê !#
xi^I
1. hypersensitivity 2. cluster of differentiation J~
*>pp#U
3. adhesion molecules 4. supper antigen 5. split tolerance QMDkkNK
¶þ¡¢ ÎÊ´ðÌâ 9c0
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ .H&XPW
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ 6]HMhv
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ .+
lx}#-#
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ (&_~eYZU
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿
Udjn.D
T=g2gmo9
$o)}@TC
eG.s|0`
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ j:^gmZ
;J
רҵ¿Î ÃâÒßѧ .^ba*qb`{
Ò»¡¢ Ãû´Ê½âÊÍ dtV7YPz4+
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å ClPE_Cfw~
5. GVHR $$B#S'
¶þ¡¢ ÎÊ´ðÌâ 4P7r\hs
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷ÓᣠlpbcpB
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ .GCJA`0h
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£ R|*Eg,1g -
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ eK\i={va
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ og4mLoLA
Ju"c!vu~
=W gzj|Kr
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ +z~bH!$2
fM(~>(q&
r#J_;P{U
רҵ¿Î ÃâÒßѧ 7oCY@>(f
Ò»¡¢Ãû´Ê½âÊÍ .k,,PuP
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å B~YOU3
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ '*G8;91u
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ Y/L*0M.<
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ YQR[0Y&e=
Èý¡¢ ÎÊ´ðÌâ bUuQ"!>ppu
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ |[
)pQGw
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ M'pIAm1p
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà ZT<VDcP{
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ }LoMS<O-[
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ LMLrH.
{r#uD5NJ/
KppYe9?
$gCN[%+j
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 1So`]N4
&_\;p-1:
:OA;vp~$x
רҵ¿Î ÃâÒßѧ nXERj; Q"
Ò»¡¢Ãû´Ê½âÊÍ i*T
-9IP
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó !Yz
CK*av1
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ \:2z!\iP`
Èý¡¢ ÎÊ´ðÌâ <s$Jj><
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ 4,BJK`{
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ .Y^pDR12
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ BQ B<+o'
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ @S6@pMo,
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ uII! ?
w zi7pJjXh
a;\a>N4
.eyJ
<b9
{~XAg~
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ 0-/@-qV\
Ò»¡¢Ãû´Ê½âÊÍ e{^^u$C1.e
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï t[MM=6|Wb
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó bgkBgugZhX
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ hDc2T
¶þ¡¢ ÎÊ´ðÌâ T# gx2Y
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ $9u:Ox
2
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ J|VDZ# c7
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ xc7Rrh]}
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ G3
h"Eo?>g
Rm~8n;7oOr
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ dJlK'zK
Ò»¡¢ Ãû´Ê½âÊÍ {aUv>T"c
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ f*T}Ov4
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ }g:'K
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© p\Iy)Y2Lf!
10¡¢ ÒõÐÔÑ¡Ôñ x'SIHV4M@Q
¶þ¡¢ ÎÊ´ðÌâ -
b`
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 qOa*JA`
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ ^s$U
n6v[
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 ~RZN+N
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ s!1/Bm|_T
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. muKu@nshL
&v Q5+
Ak$9\Sl
6="o&!
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ )Lk2tv
r
RN;#H_
q
b{X.lz0
רҵ¿Î ÃâÒßѧ kV3LFPf>0
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ NGEE'4!i7T
1. Cytokines 2. adhesion molecules 3. graft versus host reaction A5[kYD,_
4. immunologic tolerance 5. Opsonization Bg
ai|l
Èý¡¢ ÎÊ´ðÌâ $"#M:V@
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷Óᣠ"cbJ{ G1pk
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ >xH?`I7;f
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ j
J54<.D
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ YF %]%^n
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ tA9Ew{3s
T>&dPVmG,
dkg+_V!
pTJ_DH
&?gcnMg$,J
n"R$b:
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ 0|4R8Dh*-
TBHd)BhI.
:MH=6
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ HhzP Kd
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ `2xt%kC
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê dp3TJZ+U
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ Q0Gfwl
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û h5^We"}+
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö g](&H$g
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð :rvBx"
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ 2[KHmdgtB
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ zS?DXE
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© E/E|*6R
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ zEeix,I
U
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ fY|vq
amA;
a$LoQ<f_
HZ\=
NDz
\/r]Ra
F<
,"{L
.GW)"`HbU
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ ?Y9VviC
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ ay=f1<a
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ AgdU@&^
0LP>3"Sm
Ò»¡¢ Ãû´Ê½âÊÍ 1mx;b)4t
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß JOki4N
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò /j(<rz"j
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô ITjg]taD
¶þ¡¢ÎÊ´ðÌâ o^BX:\}
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ z'EphL7r
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì 5eas^Rm
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì eZ(o _
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ ]T>YYz
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ A@ w9_qo
By0Zz